Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667886 | 0.92 | ALDH1A1 (0.40) | ALDH1A1PKMKMT2ACYP2C19MITF | |
| SCHEMBL5667988 | 0.90 | ALDH1A1 (0.38) | ALDH1A1PKMKMT2ACYP2C19MITF | |
| SCHEMBL1798181 | 0.75 | MAPK1 (0.32) | — | |
| SCHEMBL1798349 | 0.72 | CYP2C19 (0.44) | ALDH1A1PKMCYP2C19MITFPOLB | |
| SCHEMBL27262043 | 0.69 | ALDH1A1 (0.54) | ALDH1A1PKMKMT2AMITFPOLB | |
| SCHEMBL28290787 | 0.69 | ALDH1A1 (0.54) | ALDH1A1PKMKMT2AMITFPOLB | |
| SCHEMBL28290789 | 0.69 | ALDH1A1 (0.57) | ALDH1A1PKMKMT2AMITFPOLB | |
| SCHEMBL20555074 | 0.68 | NPSR1 (0.44) | ALDH1A1PKMCYP2C19MITFPOLB | |
| SCHEMBL13113850 | 0.68 | ALDH1A1 (0.60) | ALDH1A1PKMKMT2AMITFPOLB | |
| SCHEMBL63286 | 0.67 | ALDH1A1 (0.59) | ALDH1A1PKMKMT2AMITFPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1934091-B | imidazole compounds for the treatment of neurodegenerative disorders | PFIZER PRODUCTS INC. (US) | 2012-02-08 | — | — | CN | disclosed |
| US-7951958-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7795447-B2 | 4-(Acylaminoacetylamino)imidazole derivatives, e.g., methyl 3-(4-{2-[2-(3,5-Difluorophenyl)acetylamino]pentanoylamino}imidazol-1-yl)butyrate; treating neurodegenerative and/or neurological disorders such as Alzheimer's disease and Down's Syndrome | PFIZER INC (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-09-18 | — | — | US | disclosed |
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | disclosed |
| CN-1934091-A | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | ALDH1A1 1117/4885PKM 1331/4885KMT2A 2382/4885 |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | ALDH1A1 1117/4885PKM 1331/4885KMT2A 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.